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Using Clinical Scenarios to Understand
Preventability of Clostridium difﬁcile Infections
by Inpatient Antibiotic Stewardship Programs
Clostridium difﬁcile infections (CDIs) pose an urgent threat to
public health.1 Both the Society for Healthcare Epidemiology
of America (SHEA) and the Infectious Diseases Society of
America (IDSA) recommend 2 approaches to combat CDI:
(1) infection prevention interventions to limit transmission of
C. difﬁcile from infected patients and (2) antimicrobial
stewardship to limit unnecessary antimicrobial use. Antibiotic
stewardship programs (ASPs) have been shown to effectively
in reduce CDI, but ASPs cannot directly address non-
antimicrobial factors that contribute to CDI, including
chemotherapy, immunosuppressant medications, surgery,
gastrostomy or jejunostomy tubes, gastric acid suppression,
and consumption of processed meats.2,3
Thus, we designed a 2-phase study (1) to deﬁne the types of
CDI that clinicians consider unlikely preventable by inpatient
ASPs and (2) to estimate the relative proportion of inpatient
CDI cases at a tertiary-care hospital that belongs to this
category of “nonpreventable” CDI.
This study was conducted at Duke University Hospital
(DUH), a 924-bed, quaternary-care, academic medical center.
First, study investigators presented 11 hypothetical clinical
scenarios with various CDI onset locations (ie, hospital onset
[HO] vs community onset [CO]), preceding antibiotic expo-
sure, and stewardship interventions (eg, change of antibiotic).
We queried 29 infectious diseases physicians using a 2-step
Delphi survey to determine the perceived preventability of
CDI.4 Each respondent was asked to use a 5-point Likert scale
to indicate whether they agreed that the CDI scenario would be
preventable by an inpatient ASP. In round 2, participants were
provided the average responses from round 1 and were asked
to repeat the survey. Consensus was deﬁned a priori as >80%
of respondents indicating “strongly agreed” and/or “agreed” or
“strongly disagreed” and/or “disagreed.” In round 1, 22 indi-
viduals responded, and 10 responded in round 2. Answers
from round 2 were used to determine consensus except when
participants failed to respond in round 2, in which case the
responses from round 1 were used.
Second, we performed a retrospective cohort study of CDI
cases among inpatients at DUH from January to December
2014. CDI cases were extracted from the infection control
database. CDI cases were deﬁned using National Healthcare
Safety Network (NHSN) surveillance deﬁnitions and were
categorized as hospital onset (HO CDI), community onset
(CO CDI), or community-onset healthcare-associated (CO-
HCFA CDI).5 Patient records were reviewed to determine
whether antibiotics had been administered during the current
hospitalization prior to CDI diagnosis. Additionally, records
from 5% of the cohort patients were reviewed to validate CDI
cases and probable location of acquisition. The DUH Institu-
tional Review Board approved the study.
Survey respondents agreed that 4 CDI scenarios were unli-
kely to be prevented by inpatient ASP efforts: CO CDI, CO-
HCFA CDI, HO CDI in the absence of preceding antibiotics,
and relapse of HO CDI (Table 1).
A total of 432 CDI cases were detected during the study
period; 183 cases (42%) belonged to 1 of the 4 previously
mentioned scenarios deemed to be unlikely to be prevented by
inpatient ASP according to the Delphi survey results (Table 1).
Of these 183 cases, 123 cases (67%) were CO CDI, 36 cases
(20%) occurred in HO-CDI patients without recorded
antibiotic exposure within 90 days, 20 cases (11%) were CO
HCFA, and 4 (2%) were relapsed HO CDI. In addition, in
19 HO-CDI cases, patients received a single dose of antibiotics,
either for surgical prophylaxis or empirical therapy, prior to
developing CDI.
We found that nearly half of all CDI cases at our hospital
were unlikely to be prevented by activities of an inpatient ASP.
While numerous studies show the beneﬁts of ASPs, our study
is the ﬁrst to describe the proportion of CDI cases unlikely to
be prevented by inpatient ASPs. In our cohort study, most
“nonpreventable” cases were CO CDI cases (67%). CO CDI
cases made up 28% of all CDIs detected during the study
period. Because other studies found that approximately 50%
of hospitalized CDI cases are CO,6 an even greater proportion
of CDI cases at other hospitals may not be prevented by
activities of their local inpatient ASPs.
While inpatient ASPs may not be able to affect the devel-
opment of CO CDI, interventions implemented by outpatient
ASPs could have a big impact because most antibiotics are
prescribed in the outpatient setting, where overuse is common.
Moreover, 2 prior systematic reviews have concluded that
outpatient ASPs can reduce inappropriate use and/or selection
of antibiotics.7,8 Indeed, the Centers for Medicare and Medi-
caid Services (CMS) has commenced discussions on policies
relating to ASP interventions in ambulatory clinics and in
long-term-care facilities outside acute-care hospitals.9 Our
data support the need for more comprehensive outpatient ASP
interventions.
This study had several limitations. First, the study was per-
formed at a single academic center and the results may not be
applicable to all hospitals. Second, the 11 clinical scenarios
used in the survey were not representative of all possible CDI
cases. Finally, there was a low response rate in round 2 of the
survey.
In conclusion, a subset of hospitalized CDI cases, including
community-onset cases and cases arising in patients without
preceding inpatient antimicrobial exposure, are unlikely to be
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prevented by an inpatient ASP. These ﬁndings suggest that
key stakeholders must (1) expand outpatient antimicrobial
stewardship programs to address unnecessary antimicrobial use
outside of hospital settings and (2) devise new strategies to
prevent CDIs that occur in the absence of antimicrobial expo-
sure or following appropriate antimicrobial exposure. Such
strategies include selective use of vaccines and new technologies
to assess and manipulate the microbiome in high-risk patients.
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table 1. Results of a Delphi Survey of Preventability of Clostridium difﬁcile Infection by an Inpatient Antimicrobial Stewardship Program
and the Proportion of “Nonpreventable” Cases at Duke University Hospital, 2014









No. (%) (N= 432)
“Nonpreventable” Based on Survey Consensus
Community onset CDI 21 (95) 21 (95) 123 (28)
Community onset healthcare-associated CDI 19 (86) 19 (86) 20 (5)
Hospital onset, absence of antibiotic exposure 17 (77) 18 (82) 36 (9)
Hospital onset, relapsed CDI 18 (82) 18 (82) 4 (1)
Total 183 (42)







Hospital onset, recurrent CDI 14 (64) 14 (64) …
Hospital onset, antibiotics deemed appropriate by ASP review 17 (77) 16 (72) …
Hospital onset, inpatient ASP changed antibiotics but CDI occurred within 24 h of change 17 (77) 15 (68) …
Hospital onset, inpatient ASP changed antibiotics to another broad-spectrum agent 11 (50) 11 (50) …
Hospital onset, inpatient ASP changed antibiotics to decrease risk of CDI 14 (64) 14 (64) …
Hospital onset, inpatient ASP considered antibiotics appropriate but decreased duration 14 (64) 15 (68) …
Hospital onset, patient did not qualify for inpatient ASP review 14 (64) 14 (64) …
NOTE. DUH, Duke University Hospital; ASP, antimicrobial stewardship program, CDI, Clostridium difﬁcile infection.
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Neonatal Outbreak of Methicillin-Resistant
Staphylococcus aureus Clone Geraldine:
A Bundle of Measures to Halt Transmission
Methicillin-resistant Staphylococcus aureus (MRSA) outbreaks
are frequent in neonatal intensive care units (ICUs).1 Toxic-
shock-syndrome toxin 1 (TSST-1)–producing MRSA Geraldine
clone represented 6.3% of invasive MRSA isolates in France in
2006 and 2007,2 and has been implicated in one outbreak
among newborns.3 We describe here a neonatal MRSA
Geraldine clone outbreak.
On March 31, 2014, a TSST-1–positive MRSA was isolated
in bronchial aspirates from 2 ICU neonates (case patients 3
and 4) (Figure 1). Our subsequent investigation identiﬁed 2
prior cases of TSST-1 MRSA carriage, the index case 1 by
umbilical swab in November 2013 and case 2 by bronchial
aspirate in December 2013. A case was deﬁned as a positive
culture for an MRSA strain expressing TSST-1 and/or speciﬁc
antibiotic susceptibility in a patient hospitalized in the neo-
natal ICU or general neonatal ward. In total, we identiﬁed 8
cases (7 cases of carriage and 1 skin infection) over a 9-month
period (Figure 1). All case patients were premature (26–
30 weeks gestation; mean birth weight, 975.2 g) and were
hospitalized in the neonatal ICU. Among them, the mean
interval of MRSA carriage detection was 25.1 hospitalization
days, and mean length of ICU stay was 33.1 days. During the
outbreak, case surveillance consisted of weekly nasal S. aureus
carriage screening of the neonates of both wards; this proce-
dure remained in place for 5 months after the last case was
discovered. All MRSA isolates expressed resistance to penicillin
G, methicillin, kanamycin, tobramycin, and fucidic acid
according to guidelines of the French Antibiogram Commit-
tee. All of the isolates were typed by the National Reference
Center for staphylococci (S. aureus Genotyping Identibac,
Alere, Waltham, MA) and were identiﬁed as the Geraldine
clone, which is characterized by the following criteria:
(1) sequence type ST5, agr2, (2) positivity for TSST-1, enter-
otoxins SEC, SED, SEJ, SEL, and SER as well as the egc locus,
and (3) negativity for Panton-Valentine leukocidin.4 All case
isolates underwent molecular analysis except strains from
cases 1 and 2, as these strains had not been stored.
Immediately after the alert, we implemented contact
precautions (ie, glove and gown usage) for HCP in contact
with infected and colonized neonates. We also held informa-
tion meetings for healthcare personnel (HCP) and audited
HCP practices. The audit revealed a lack of consistency
in standard precaution application and hygiene practices.
The control measures implemented consisted of team support
for multidrug-resistant bacteria management, standard
precautions, and hand-hygiene reinforcement. We focused
on the use of hydroalcoholic solutions, lack of hand jewelry
veriﬁcations, and daily changes of work outﬁts. We assessed the
effectiveness of these measures using indicators such as bedsore
prevalence, cleaning activities records, environmental samples,
and compliance with hand hygiene procedures, which was
assessed by hydroalcoholic solutions consumption according to
French guidelines.5 Compliance to theminimum hydroalcoholic
consumption, calculated according to clinical activity, increased
from 57.4% 6 months before the outbreak to 84.4% during the
outbreak to 102.9% 6 months after the outbreak.
We sought environmental links between cases. In total, 60
environmental swabs and 20 surface samples from patient
rooms, drug preparation area, transfrontanellar ultrasound
apparati, and x-ray devices were tested between May 3 and
June 25, 2014. No medical devices or environmental sources
were found to be involved in transmission.
Despite the control measures, transmission continued.
Some carrier neonates were hospitalized in neighboring rooms
(Figure 1), suggesting possible cross transmission via HCP
hands, especially because HCP compliance to the measures
was not consistent at the beginning of the outbreak. In addi-
tion, S. aureusmay have been spread by airborne transmission
by HCP.6 The long interval between the ﬁrst 2 and subsequent
6 cases also pointed to HCP carriage. HCP are often involved
in horizontal MRSA transmission to neonates,6,8 and HCP
decolonization is a proven outbreak control measure.3,7,8 We
opted for universal decolonization of all HCP, both permanent
and rotating staff (including students, radiology technicians,
radiologist physiotherapist, psychologist, milk-bank techni-
cians, cleaning staff, social workers, laboratory couriers, and
secretaries), regardless of their screening results, in order to
cover the risk of false negatives due to intermittent carriage.
We sampled both the noses and throats of the HCWs to
improve sensitivity.9 Decolonization consisted of a 5-day
course based on twice-daily mupirocin nasal ointment and
daily showering with chlorhexidine soap,10 which were dispensed
to each HCP during screening interviews to promote
adherence. HCP voluntarily participated in decolonization; no
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